Showing 1 - 10 of 804
Persistent link: https://www.econbiz.de/10010207164
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10010281440
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10005423798
Persistent link: https://www.econbiz.de/10010517756
Persistent link: https://www.econbiz.de/10011427811
Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...
Persistent link: https://www.econbiz.de/10010526909
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Persistent link: https://www.econbiz.de/10013163669
Persistent link: https://www.econbiz.de/10012512495
Persistent link: https://www.econbiz.de/10012391533